Kisqali Helps Treat Early-Stage Breast Cancer

At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone. Listen to the podcast to hear Dr. Slamon explain: why he thought Kisqali could benefit people with early-stage breast cancer the side effects Kisqali can cause what the results mean for people diagnosed with early-stage, hormone receptor-positive disease